Liabilities and Equity of Y-mAbs Therapeutics, Inc. from 31 Dec 2017 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Y-mAbs Therapeutics, Inc. quarterly Liabilities and Equity in USD history and change rate from 31 Dec 2017 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Liabilities and Equity for the quarter ending 30 Jun 2025 was $117,211,000, a 19% decline year-over-year.
Source SEC data
View on sec.gov
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Liabilities and Equity (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $117,211,000 -$26,824,000 -19% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $112,613,000 -$10,702,000 -8.7% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $119,904,000 -$7,965,000 -6.2% 31 Dec 2024 10-Q 08 Aug 2025 2025 Q2
Q3 2024 $120,917,000 -$7,967,000 -6.2% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $144,035,000 +$11,639,000 +8.8% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $123,315,000 -$14,130,000 -10% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $127,869,000 -$13,587,000 -9.6% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $128,884,000 -$15,031,000 -10% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $132,396,000 -$32,782,000 -20% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $137,445,000 -$53,602,000 -28% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $141,456,000 -$71,327,000 -34% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $143,915,000 -$96,064,000 -40% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $165,178,000 -$94,301,000 -36% 30 Jun 2022 10-Q 08 Aug 2022 2021 Q3
Q1 2022 $191,047,000 -$83,869,000 -31% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $212,783,000 +$80,736,000 +61% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $239,979,000 +$96,784,000 +68% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $259,479,000 +$92,150,000 +55% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $274,916,000 +$80,842,000 +42% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $132,047,000 -$84,319,000 -39% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $143,195,000 +$39,511,000 +38% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $167,329,000 +$41,289,000 +33% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $194,074,000 +$54,077,000 +39% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $216,366,000 +$64,442,000 +42% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $103,684,000 -$62,710,000 -38% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $126,040,000 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $139,997,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $151,924,000 +$59,797,000 +65% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $166,394,000 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q4 2017 $92,127,000 31 Dec 2017 10-K 22 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.